The Valley Desk

NCT07444489 · Interventional trial

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

Overall registry status Enrolling by invitation

Phase 3

Conditions Antibody-mediated Rejection, Microvascular Inflammation

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov